{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:26:00Z","timestamp":1780590360192,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-06481-4","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:29:09Z","timestamp":1736501349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimization of antidepressant treatment by pharmacogenomics: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"issue":"10440","key":"6481_CR1","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","volume":"403","author":"Burden of disease scenarios","year":"2024","unstructured":"Burden of disease scenarios. For 204 countries and territories, 2022\u20132050: a forecasting analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2204\u201356.","journal-title":"Lancet"},{"key":"6481_CR2","doi-asserted-by":"publisher","first-page":"114754","DOI":"10.1016\/j.psychres.2022.114754","volume":"317","author":"MM Weissman","year":"2022","unstructured":"Weissman MM. Pursuing the epidemiology and familial risks of depression and developing an evidence based psychotherapy. Psychiatry Res. 2022;317:114754.","journal-title":"Psychiatry Res"},{"issue":"2","key":"6481_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/07853890600551045","volume":"38","author":"EB Binder","year":"2006","unstructured":"Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med. 2006;38(2):82\u201394.","journal-title":"Ann Med"},{"issue":"11","key":"6481_CR4","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"6481_CR5","doi-asserted-by":"crossref","unstructured":"Jha MK, Trivedi MH. Personalized antidepressant selection and pathway to novel treatments: clinical utility of targeting inflammation. Int J Mol Sci. 2018;19(1).","DOI":"10.3390\/ijms19010233"},{"key":"6481_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pharmthera.2019.01.002","volume":"197","author":"VM Lauschke","year":"2019","unstructured":"Lauschke VM, Zhou Y, Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 2019;197:122\u201352.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"6481_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bpsgos.2021.07.008","volume":"2","author":"O Pain","year":"2022","unstructured":"Pain O, Hodgson K, Trubetskoy V, Ripke S, Marshe VS, Adams MJ, Byrne EM, Campos AI, Carrillo-Roa T, Cattaneo A, et al. Identifying the common genetic basis of antidepressant response. Biol Psychiatry Glob Open Sci. 2022;2(2):115\u201326.","journal-title":"Biol Psychiatry Glob Open Sci"},{"issue":"2","key":"6481_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cger.2017.01.009","volume":"33","author":"KT Bain","year":"2017","unstructured":"Bain KT, Knowlton CH, Turgeon J. Medication risk mitigation: coordinating and collaborating with health care systems, universities, and researchers to facilitate the design and execution of practice-based research. Clin Geriatr Med. 2017;33(2):257\u201381.","journal-title":"Clin Geriatr Med"},{"issue":"3","key":"6481_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1055\/a-0606-5240","volume":"52","author":"S Englisch","year":"2019","unstructured":"Englisch S, Jung HS, Lewien A, Becker A, Nowak U, Braun H, Eisenacher S, Thiem J, Meyer-Lindenberg A, Zink M. Response to agomelatine treatment is independent of smoking status and dosage: results from the AGOPSYCH study. Pharmacopsychiatry. 2019;52(3):142\u20136.","journal-title":"Pharmacopsychiatry"},{"key":"6481_CR10","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.crphar.2022.100112","volume":"3","author":"TT Luong","year":"2022","unstructured":"Luong TT, Powers CN, Reinhardt BJ, Weina PJ. Pre-clinical drug-drug interactions (DDIs) of gefitinib with\/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. Curr Res Pharmacol Drug Discov. 2022;3:100112.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"6481_CR11","doi-asserted-by":"crossref","unstructured":"Zubiaur P, Fern\u00e1ndez-Campos P, Navares-G\u00f3mez M, Soria-Chacartegui P, Villapalos-Garc\u00eda G, Rom\u00e1n M, Mej\u00eda-Abril G, Ochoa D, Abad-Santos F. Variants in COMT, CYP3A5, CYP2B6, and ABCG2 alter quetiapine pharmacokinetics. Pharmaceutics. 2021;13(10).","DOI":"10.3390\/pharmaceutics13101573"},{"issue":"7","key":"6481_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"6481_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1124\/dmd.108.023291","volume":"37","author":"GV Bakken","year":"2009","unstructured":"Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37(2):254\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"6481_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ps.201300059","volume":"65","author":"DA Mrazek","year":"2014","unstructured":"Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013. Psychiatr Serv. 2014;65(8):977\u201387.","journal-title":"Psychiatr Serv"},{"issue":"8","key":"6481_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/pgs-2019-0157","volume":"21","author":"L Brown","year":"2020","unstructured":"Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, Brown K, Jablonski MR, Dechairo B. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics. 2020;21(8):559\u201369.","journal-title":"Pharmacogenomics"},{"key":"6481_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119\u201337.","journal-title":"Annu Rev Med"},{"key":"6481_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fpsyt.2020.00094","volume":"11","author":"R van Westrhenen","year":"2020","unstructured":"van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Juki\u0107 MM. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry. 2020;11:94.","journal-title":"Front Psychiatry"},{"issue":"5","key":"6481_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.mp.4001494","volume":"9","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockm\u00f6ller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442\u201373.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"6481_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cll.2008.05.006","volume":"28","author":"A Seeringer","year":"2008","unstructured":"Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med. 2008;28(4):619\u201326.","journal-title":"Clin Lab Med"},{"issue":"1","key":"6481_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116\u201324.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"6481_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gim.2016.87","volume":"19","author":"KE Caudle","year":"2017","unstructured":"Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215\u201323.","journal-title":"Genet Med"},{"key":"6481_CR22","first-page":"41","volume":"17","author":"OGJ Deardorff","year":"2018","unstructured":"Deardorff OGJ, Leanard V. Making sense of CYP2D6 and CYP1A2 genotype vs phenotype. Curr Psychiatry. 2018;17:41\u20135.","journal-title":"Curr Psychiatry"},{"issue":"4","key":"6481_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/0269881119827959","volume":"33","author":"M Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez M, Ochoa D, Belmonte C, Rom\u00e1n M, Vieira de Lara D, Zubiaur P, Koller D, Mej\u00eda G, Abad-Santos F. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33(4):522\u201331.","journal-title":"J Psychopharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06481-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:04:00Z","timestamp":1736503440000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06481-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6481"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06481-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Medical Ethics Committee of Anding Hospital in Tianjin, with the approval number: 2024-12.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}